Prologue {#Sec1}
========

Avian infectious bronchitis (IB) is an acute, highly contagious upper respiratory tract disease affecting chicken of all ages with significant economic threat to the poultry industry. It is caused by infectious bronchitis virus (IBV), which belongs to the genus *Gammacoronavirus*, family *Coronaviridae*, in the order *Nidovirales*. The disease causes symptoms like watery eyes, mucus in the nares and trachea, sneezing, tracheal rales, and coughing. In layer birds, IB results in decreased egg production as well as quality, and some IBV variants cause interstitial nephritis. Infection with IBV causes ciliostasis in the trachea and predisposes to the secondary pathogens further complicating the disease. Morbidity is always 100%; however, mortality can vary from 0 to 82% depending upon the age of the birds, immune status, strain of the virus, and involvement of secondary pathogens. The virus possesses a single copy of positive-sense single-stranded RNA as its genome, which is approximately 27.6 kb in size. The genome undergoes genetic recombination and spontaneous mutation leading to the emergence of new variants having low level of cross-protection and complicates the control program by vaccination (Cavanagh and Gelb [@CR23]; Jackwood et al. [@CR63]). The IBV-like coronaviruses were also detected in pheasant, peafowl, turkey, teal, geese, pigeon, guinea fowl, partridge, penguins, and ducks (Dea and Tijssen [@CR38]; Jonassen et al. [@CR69]; Cavanagh [@CR21]; Circella et al. [@CR27]). The IBV is worldwide in distribution, and infection is acquired through inhalation or direct contact with infected birds or premises. Vertical transmission is not reported. Some of the IBV strains can also replicate in the kidneys, reproductive tract, and enteric surfaces resulting in the development of nephritis, misshapen eggs, and enteritis, respectively (Boltz et al. [@CR12]). Induction of apoptosis in kidney cells is a major contributor of pathogenicity for virulent nephropathogenic IBV (Liu et al. [@CR89]). The disease affects both egg and meat type of chickens. Respiratory disease is observed in the young growing chickens while reduced weight gain and feed efficiency in broiler chickens. IBV infection predisposes the broiler birds to secondary bacterial infection resulting in airsacculitis, pericarditis, and perihepatitis. In layers and breeder chickens, IBV replicates in the oviduct causing permanent damage or limited egg production. Pigment of the affected shell becomes paler and albumin is watery in consistency. The virus has not been reported to cause human infection.

The virus contains lipid envelope with a round to pleomorphic shape. The virus particles are approximately 120 nm in diameter with club-shaped spikes in their surface, which provide them a crown-like appearance (Jackwood and de Witt [@CR60]). The genome encodes 4 structural proteins, 15 nonstructural proteins (nsp 2--16), and at least 5 lineage-specific accessory proteins (Dent et al. [@CR39]). Structural proteins are spike (S), membrane (M), small membrane (E), and nucleoprotein (N). The spike protein is post-translationally cleaved into S1 and S2 subunits where the former is involved in virus entry to the host cell via sialic acid receptor and also harbors virus-neutralizing epitopes (Lai and Cavanagh [@CR83]; Cavanagh [@CR22]; Cavanagh et al. [@CR24]; Koch et al. [@CR79]; Niesters et al. [@CR102]). S2 subunit anchors the spike protein, and the ectodomain of S2 protein also aids in the attachment of virus to the host cells (Promkuntod et al. [@CR109]). M protein is the most abundant transmembrane protein that interacts with N and S glycoprotein for virion assembly (de Haan et al. [@CR34]; Bande et al. [@CR8]). E protein is scant and confined to the Golgi apparatus of the infected cell. This protein plays a key role in viral envelope formation, assembly, budding, ion channel activity, and apoptosis (Corse and Machamer [@CR32]; Wilson et al. [@CR126]). Ribonucleoprotein is formed by interaction of N protein to the genomic RNA of IBV and aids in transcription, replication, and translation of viral genome (Jayaram et al. [@CR65]).

History {#Sec2}
=======

Schalk and Hawan in [@CR115] first reported a respiratory disease of chick that is characterized by gasping and listlessness in North Dakota, USA. Two years later, similar disease was reported by Bushnell and Brandly. Since the disease could be transmitted by Berkefeld filtered material, they recognized the causative agent as filterable virus and was confused with infectious laryngotracheitis virus (ILTV; Bushnell and Brandly [@CR17]). The causative agent was established in [@CR10] by Beach and Schalm who proved that IBV was distinct from ILTV by cross-immunity studies. Although young chicks were found to be affected by IBV, later it was observed to be common in mature and laying hens. IBV was first cultivated in chick embryos by inoculating through chorioallantoic membrane (CAM). Unlike ILT, IBV did not show distinctive lesions on CAM and rather resulted in embryo death (Beaudette and Hudson [@CR11]). Jungherr and coworkers first reported more than one serotypes of IBV. It has been shown that Massachusetts (Mass) isolate in 1941 and Connecticut (Conn) isolate in 1951 produced identical disease but did not cross-protect each other (Jungherr et al. [@CR72]).

Transmission and Risk Factor {#Sec3}
============================

IBV is a highly infectious disease and birds show clinical signs within 36--48 h of infection. Infected chicks are the major source of virus contamination in the environment. Virus is transmitted through respiratory secretions and fecal droplet from infected chicken. Virus may also spread from one flock to another through inanimate objects including contaminated utensils, egg-packing materials, fertilizer, and farm visit. Vertical transmission of virus has not been reported. Trachea, kidney, and bursa of Fabricius show the presence of the virus as early as 24 h and through the seventh day following aerosol transmission (Cavanagh and Gelb [@CR23]). The presence of virus in the cecal tonsils up to 14 weeks and from the feces up to 20 weeks correlates with the viral transmission through fecal shedding (Alexander and Gough [@CR3]). Birds recover from infection within 14 days with a rise in antibody titer. It has been reported that IBV re-excreted from virus-negative birds for several weeks following recovery from inoculation at 1 day of age. Isolation of virus from tracheal and cloacal swabs at the time of lay and 19 weeks of age was reported (Jones and Ambali [@CR71]). Establishment of latent infection and erratic shedding of virus in feces and respiratory secretion for a prolonged period of time are possible in a very few cases (Ignjatovic and Sapats [@CR58]). Kidney may be one of the sites of persistent infection (Raj and Jones [@CR113]). Vaccine viruses persist up to 163 days or more in various internal organs (Gay [@CR49]). Prolonged or intermittent shedding of virus is considered as a potential risk factor for transmission of virus from one flock to another through contaminated equipment or persons.

Incidence and Prevalence {#Sec4}
========================

Spontaneous mutation of S1 subunit of S gene resulted in the emergence of various serotypes (Abro et al. [@CR2]). IBV strains can be classified by genotyping- and serotyping-based methods. Viral serotypes can be distinguished by cross-neutralization test and genotypes by reverse transcriptase polymerase chain reaction (RT-PCR) techniques, bioinformatics, and gene sequencing technology. S1 gene of IBV variants can be amplified and the sequences are analyzed by Basic Local Alignment Search Tool (BLAST; Posada and Crandall [@CR108]). IBV strains like Mass, 4/91, D274, and QX-like are reported worldwide. Some of the IBV strains are more prevalent in particular geographical location. M41, Arkansas (Ark) and Conn are common in the United States, while 4/91 (793/B, CR88) and D274 are predominant strains in Europe. In recent times, the Chinese QX variants have caused outbreaks in Europe, Asia, the Middle East, and Africa (Bande et al. [@CR8]).

Predominant strains of IBV isolated in China are QX-like strains (Ma et al. [@CR93]). IBV QX strain-affected chickens showed proventriculus swelling which was first documented in 1996 (Yudong et al. [@CR132]). The proportion of QX isolates has increased from 20% in 2000 to 60% in 2007. Recent isolates in China are LDT3 and 4/91 (Feng et al. [@CR45]; Li et al. [@CR85]; Ji et al. [@CR66]). Attenuated live strains such as H120, LDT3, 4/91, and inactivated M41 are the commercially used vaccine strains in China. Previous studies reported that Mass type of strains is widely in circulation. Recombination of Mass type with other strain resulted in complete cross-protection of Mass strain by H120 strain. However, two recombinant strains (CK/CH/LDL/110931 and CK/CH/LHB/130573) are highly variable in S1 gene from Mass type and are not cross-neutralized by H120 strain (Chen et al. [@CR25]; Han et al. [@CR55]). Since 2009, the emergence of Taiwan group (TW-I and TW-II) of strains have been increased in China (Xu et al. [@CR128]; Feng et al. [@CR45]; Zou et al. [@CR136]; Luo et al. [@CR92]). Recombinants GD strain, created from QX and TW-I strains, induced renal lesions, respiratory symptoms, and 40% mortality (Xu et al. [@CR128]; Yan et al. [@CR129]). JP-I, JP-II, and JP-III are three genetic groups of IBV in Japan. Different variants of 4/91 strains are isolated (Inoue et al. [@CR59]; Shimazaki et al. [@CR118]). Two variants of 4/91 strain (JP/Wakayama/2003 and JP/Iwate/2005) are cross-neutralized by 4/91, JP-I and 4/91, JP-II strains, respectively. Ibaraki strain isolated in 2009 was distinctly related to other Japanese strain. Korean group-I and group-II are the two genetic groups of IBV that exist in Korea. Group-I is closely related to Mass type. There are three subgroups of group-II, namely, KM91-like, New Cluster 1 (NC1), and QX-like (Lim et al. [@CR86]). Korean group-II isolates that emerged from 2005 to 2010 were nephropathogenic (Lim et al. [@CR86]). Since 2009, predominant isolates circulating in Thailand are QX-like variants (Promkuntod et al. [@CR110]). Indian IBV isolate PDRC/Pune/Ind/1/00 was found to have a unique S1 sequence compared to reference strains from the United States, Europe, Mexico, and Australia and found as nephropathogenic (Bayry et al. [@CR9]). 4/91 type strain was first isolated in India by Sumi et al. in [@CR119]. An Indian IBV strain (India/LKW/56/IVRI/08) showed 99% homology with a Thailand strain (THA280252), while another isolate (India/NMK/72/IVRI/10) showed similarity with the United Kingdom (4/91 pathogenic strain), Japan (JP/Wakayama/2/2004), and China (TA03) (Sumi et al. [@CR119]). Indian strain that was isolated in [@CR106] by Patel and coworkers was similar to Mass type vaccine M41 strain. Six IBV genotypes, namely, 4/91, IS/1494/06, Mass, IS/885/00, Q1, and D274, were detected in the Middle East from 2009 to 2014 (Ganapathy et al. [@CR48]). Analysis of complete genome sequence of a field strain of IBV from the northern part of India indicated the emergence of a genotype I variant of IBV (Jakhesara et al. [@CR64]). China-like strains (CK/CH/Guangdong/Xindadi/0903 and CK/CH/LDL/97I) are also reported in the Middle East (Seger et al. [@CR116]; Ababneh et al. [@CR1]). LDL/97I-like strains isolated in the Middle East showed extensive tissue tropism such as trachea, kidneys, ovarian tissue, and cecal tonsils, whereas original LDL/97I strains were limited to the respiratory system and kidneys.

IBV isolates in Egypt are divided into the Egy/Var I, Egy/Var II, and Mass type groups (Zanaty et al. [@CR133]). QX-like strains and Italy 02 type strains were first isolated in Zimbabwe (Toffan et al. [@CR120]) and Morocco, respectively (Fellahi et al. [@CR44]). Variants such as Conn, Mass, Florida, Clark 333, Ark, Holte, and Gray were identified in North America (Jungherr et al. [@CR72]; Winterfield and Hitchner [@CR127]; Brown et al. [@CR15]; Butcher et al. [@CR18]; Kinde et al. [@CR76]). However, Mass, Conn, and Ark are the common serotypes that are reported. A nephropathogenic IBV strain (DMV/1639/11) was detected in Delmarva in 2011. When a vaccine containing a mixture of Mass, Conn, and Ark administered through intraocular route, virus shedding and renal lesions were decreased following DMV/1639/11 challenge (Gelb et al. [@CR52]). Cal99 strain could affect only the respiratory tract, while Cal99 variants have a tendency to spread to the kidneys, gastrointestinal tract, and the bursa in addition to the respiratory system (Franca et al. [@CR46]). Other IBV variants such as CAV, DE072, and MX97--8147 have also been reported (Jackwood et al. [@CR61]). The D207, Mass, Conn, and Ark serotypes were detected in Brazil (Felippe et al. [@CR43]).

Immunobiology {#Sec5}
=============

Innate Immunity {#FPar1}
---------------

Toll-like receptor 3 (TLR3) on innate immune cells is involved in the early recognition of the virus (Ariaans et al. [@CR5]). TLR3 mRNA expression was more following IBV-M41 strain infection (Wang et al. [@CR125]), and upregulation of TLR3 and TLR7 mRNA was detected in the trachea and lungs when chicks were intratracheally infected with Conn strain (Kameka et al. [@CR74]). Nephropathogenic IBV infection significantly increases chicken myeloma differentiation antigen 5 (MDA5) expression in the kidneys, which indicate the role of chicken MDA5 against IBV infection (Cong et al. [@CR29]). Chicken mannose-binding lectin (MBL), a member of C-type collectin family, has antiviral activity against IBV. It binds to S1 protein of IBV and blocks the attachment of viral particles to the surface of the susceptible cells in the chicken trachea (Zhang et al. [@CR134]). In addition, MBL also plays a major role in shaping innate as well as adaptive immune responses against IBV (Hamzic et al. [@CR54]; Juul-Madsen et al. [@CR73]; Kjaerup et al. [@CR78]). Further, a high level of MBL contributes to the clearance of IBV from the trachea (Juul-Madsen et al. [@CR73]; Kjaerup et al. [@CR77]).

During viral infection, cytokines are involved in the protection of adjacent cells as well as facilitate the activation and migration of T lymphocytes to the infection site (Guo et al. [@CR53]). IBV infection induces interferon in the trachea, lung, kidney, liver, and spleen (Otsuki et al. [@CR105]). Replication of IBV strains both in vitro and in vivo was inhibited in the presence of IFN-α. Both IFN-α and IFN-β transcripts are elevated in the trachea after IBV infection. Among type I interferon, IFN-β has a dominant role in the innate immune response against IBV infection (Yang et al. [@CR131]). IFN-γ contributes to the tracheal lesions, and IFN-λ plays a major role in the host resistance against IBV especially in the trachea (Yang et al. [@CR131]). IBV can act as a polyclonal stimulator of IFN-γ production in the chicken leukocytes, which is IBV-specific as other chicken viruses were unable to do the same (Ariaans et al. [@CR6]). Proinflammatory cytokines like IL-6 and IL-1β were upregulated at 3 days post-IBV-M41 infection. These cytokines have association with increased viral load and tracheal lesions as well as defects in eggshell components in the laying hens (Okino et al. [@CR104]; Nii et al. [@CR103]).

Macrophages and heterophils are important innate immune cells during the initial phase of infection. Heterophils are the first phagocytic cells recruited at the infection site. Upon phagocytosis, heterophils degranulate cytotoxic molecules like cathepsin and bactericidal permeability increasing protein and thus try to neutralize phagocytosed pathogen. Heterophils are responsible for destruction of IBV-infected cells by phagocytosis and oxidative lysosomal enzyme release during the initial phase of infection (Guo et al. [@CR53]). Further, depletion of heterophils causes more severe nasal exudation in comparison with control when infected with IBV (Raj et al. [@CR114]). Activation of macrophages is based mainly on the action of IFN-γ (Caron [@CR20]). Macrophages were found to increase in number in the tracheal and bronchial lumen of chickens at 24 and 96 h post-IBV-M41 infection (Fulton et al. [@CR47]). Similarly, chickens infected with Conn strain significantly increased macrophages in the lungs and trachea at 24 h post-infection (hpi), suggesting the role of respiratory macrophages in limiting replication of virus within respiratory tissues (Kameka et al. [@CR74]). Recruitment of macrophages and production of IL-1β play a major role in the host responses against IBV infection (Amarasinghe et al. [@CR4]).

Adaptive Immunity {#FPar2}
-----------------

Humoral and cellular immune responses are important in the control of infection. Local antibody level but not serum antibodies are involved in the protection of respiratory tract epithelium (Raggi and Lee [@CR111]). Hyperplasia of goblet cells and alveolar mucous glands resulting in seromucous nasal discharge and catarrhal exudates in the trachea are believed to be the first component of innate immunity (Nakamura et al. [@CR100]). Serum anti-IBV IgG can be detected at 4 days post-infection (dpi) and peaking at about 21 dpi. In an in vitro study, activation of memory B cells by IBV results in the secretion of antibodies at 21 dpi (Pei and Collisson [@CR107]). IgG antibody titer was highest at 7 dpi in the lachrymal fluid and possibly remaining up to 23 dpi. Similarly, in oviduct washes, antibodies were detected at 7 and 23 dpi (Raj and Jones [@CR112]).

IBV-infected chickens showed anti-IBV IgA antibodies in the lamina propria, trachea, and between the epithelial cells of trachea (Joiner et al. [@CR68]; Nakamura et al. [@CR100]). Anti-IBV IgA was detected in the lachrymal fluid at 10 days post-live attenuated Ark DPI-type vaccination. However, there was no further increase in IgA level upon challenge, suggesting the significant role of neutralizing antibodies in reducing the potency of IBV infection at the time of challenge (Joiner et al. [@CR68]). In our lab, administration of resiquimod (R-848), a TLR-7 agonist with inactivated or live IBV vaccine increased the secretory IgA, which was mediated through the enhanced expression TGF-β4 in the chicken (Matoo et al. [@CR97]).

Humoral immunity plays an important role in recovery and clearance of viral infection. Bursectomized chicks showed increase in tissue viral load as well as severe and long-lasting illness (Cook et al. [@CR30]). As the titer of humoral antibodies increased, re-isolation of virus from kidneys and genital tract decreased (Macdonald et al. [@CR94]). This increase in antibody titer also protected against drop in egg production and viral spread from trachea to other susceptible organs (Box et al. [@CR13]; Raj and Jones [@CR113]). Conversely, it has also been shown that chickens were more susceptible to IBV with high tear antibody titer, whereas low tear antibody titer protected the birds from IBV. This suggested that not only antibody but other immune defense mechanisms are also important in clearance of infection in tear (Gelb et al. [@CR51]).

Nephropathogenic Gray strain-infected chickens showed increased IBV-specific cytotoxic T lymphocytes (CTLs) at 3 dpi with peak level at 10 dpi (Seo and Collisson [@CR117]). A study assessing the immunophenotypes of mononuclear cells in the tracheal mucosa revealed the presence of CTLs at 3 or 4 dpi suggesting the role of CTLs in viral clearance during the early phase of infection (Kotani et al. [@CR80]). CD8+ T cells play an important role in controlling IBV infection. This IBV-specific CTL activity was dependent on S and N proteins of IBV, and it can induce lysis of IBV-infected cells (Collisson et al. [@CR28]). While CD8+ T cells play an important role in early immune response, CD4+ T and B cells are involved in long-term control of IB.

Maternally Derived Antibodies {#FPar3}
-----------------------------

IgG antibodies were transferred from vaccinated hens to the respiratory mucus of newly hatched chicks (Hawkes et al. [@CR57]). One-day-old chicks with high level of maternal antibodies showed more than 95% protection against IBV-Mass strain challenge. However, this was not evident at 7 days of its age. Protection was associated with local respiratory antibodies but not with serum antibodies (Mondal and Naqi [@CR99]). Day-old chicks when vaccinated with live IBV-Mass strain showed no IBV-specific antibody response. This may be due to binding and neutralization of vaccine virus by maternal antibodies (Mondal and Naqi [@CR99]). Prime boost strategies involve vaccination with live strain followed by inactivated vaccine to protect hens throughout their laying period as well as to transfer high level of antibodies to their offspring (Chhabra et al. [@CR26]).

Diagnosis {#Sec6}
=========

Virus Isolation {#FPar4}
---------------

Since trachea is the primary site of IBV infection, tracheal swab and tracheal tissues are the preferred sampling material within 1 week of infection. Cloacal swabs or cecal tonsils are the sample of choice during postmortem examination if time is elapsed more than 1 week from the start of infection. This may be due to the initial growth of virus in the upper respiratory tract and eventual spread to the non-respiratory organs. This results in the early clearance of virus from trachea than from the intestinal tissues (Alexander and Gough [@CR3]; Jones and Ambali [@CR71]; Lucio and Fabricant [@CR91]). Based on clinical history, sampling of other organs like the lung, kidney, and oviduct should also be considered. Sentinel chickens should be placed in the problematic flock where direct sampling method is difficult. After 1 week of contact exposure, sentinels are removed for direct sampling method (Gelb et al. [@CR50]).

Isolation in Embryonated Eggs {#FPar5}
-----------------------------

Embryonated chicken eggs infected with IBV shows characteristic signs including dwarfism, curling, hemorrhages, and death (Fig. [16.1](#Fig1){ref-type="fig"}). Field samples were inoculated through intra-allantoic route of 9- to 10-day-old embryonated eggs and incubated for 4 days. Allantoic fluid were collected and again passaged to analyze the morphology of the embryo. IBV titer reaches its maximum about 1 to 2 days post-inoculation. Although chicken embryonated eggs are effective model for virus isolation, it has the drawback of need for three successive passages for manifestation of characteristic lesions. In addition, reduced virus yield may be observed when IBV is inactivated due to improper preservation (Villarreal [@CR124]).Fig 16.1Comparison of 12-day-old normal (left) and dwarfed and IBV-infected embryos (right) of the same age

Cultivation in Tracheal Rings {#FPar6}
-----------------------------

Tracheal rings were collected from 19- to 20-day-old SPF embryo and placed in a tube containing culture media and antibiotic. This was incubated for 48 h, and only the rings with more than 50% ciliary motility are used. After removing the culture media, 0.1 ml of sample was added and incubated for 1 h for viral adsorption. One ml of culture media was once again added and incubated. Tracheal rings were evaluated for ciliary motility at 24, 48, 72, and 96 h post-inoculation. Ciliary motility decreases as IBV replicates in the tracheal cells (Epiphanio et al. [@CR42]). This technique also has disadvantage of not being sensitive for IBV field samples and may result in false-negative results. Thus, IBV should be confirmed by other specific methods like virus neutralization (VN), hemagglutination inhibition (HI), ELISA, immunohistochemistry, or nucleic acid analysis or by electron microscopy.

Serology {#FPar7}
--------

Different serotypes of IBV show high amino acid similarity within N, M, and S2 protein, and hence these regions are called group-specific antigens. The antibodies against group-specific antigen of one serotype can neutralize different serotypes, while antibodies against S1 protein of the virus are type-specific and are not cross-protective between different serotypes (Cavanagh and Gelb [@CR23]). The serological tests like, ELISA, immunofluorescence, and immunodiffusion test cannot differentiate different serotypes because antibodies bind to both group- and type-specific antigens, while VN and HI are serotype-specific tests. Therefore, VN, HI, and ELISA are routinely used serological methods (de Wit [@CR35]). Precipitating antibodies in the group-specific agar gel precipitation test (AGPT) test are short lived which may lead to under-detection. Positive AGPT is indicative of recent infection. Birds infected with the same serotype as vaccine virus lead to poor production of antibodies as detected by AGPT. Thus, AGPT is not recommended for detection of IBV antibodies and rather for detection of IBV antigen (de Wit et al. [@CR36], [@CR37]). IBV ELISAs are group-specific methods and detect IBV antibodies within 1 week of infection. Paired serum samples are required with first sample collected at the beginning of infection and second sample at 4 weeks later. The first sample should be collected without any delay for detection of seroconversion. Hence, ELISA analyzes post-vaccination and infection responses by IgG detection as an indicator of humoral immunity (Cavanagh and Gelb [@CR23]). VN and HI are serotype-specific techniques for detection of antibodies induced by S1 protein. VN can be carried out in embryonated egg, cell culture, and tracheal ring culture to detect embryo alterations, cytopathic effect, and ciliostasis, respectively. This assay requires neutralizing antibodies that are highly specific and do not cross-react with other serotypes. IBV requires treatment with type C phospholipase enzyme to expose hemagglutinin. HI test usually detects antibodies between 1 and 2 weeks after infection (de Wit [@CR35]).

Antibody-Based Methods {#FPar8}
----------------------

Immunofluorescence and immunoperoxidase assays are used to detect IBV antigen from tracheal mucosa or other tissues using IBV-specific polyclonal sera or monoclonal antibodies (Handberg et al. [@CR56]). The presence of virus in the tracheal organ culture can be detected by immunofluorescence without fixation of the culture using low-power microscopy.

Nucleic Acid-Based Methods {#FPar9}
--------------------------

IBV can be detected directly from the clinical sample by real-time RT-PCR or quantitative RT-PCR (Callison et al. [@CR19]). This technique is cost- effective, as a number of samples can be examined in a short period of time, and also gives an indication of the level of viral nucleic acid in the sample. Although conventional RT-PCR identifies IBV nucleic acid, it requires passage in embryonated eggs before positive result is obtained. Swabs containing only a small amount of viral RNA can be detected by nested RT-PCR. However, this method is highly prone to cross-contamination resulting in a false-positive test. Positive RT-PCR indicates only the presence of viral nucleic acid but not IBV type. IBV types can be identified by genotyping methods by analyzing the amplicons from the S1 gene. IBV types can be differentiated based on their unique electrophoresis banding pattern using restriction fragment length polymorphism (RFLP) (Marquardt et al. [@CR96]; Nakamura et al. [@CR101]).

Recent Advances {#FPar10}
---------------

An intelligent electronic device was developed by Banakar and coworkers for fast diagnosis of Newcastle disease, IB, and avian influenza based on chicken's sound signals (Banakar et al. [@CR7]). Laamiri and coworkers developed a one-step multiplex real-time RT-PCR for simultaneous detection of four respiratory avian viruses including IBV (Laamiri et al. [@CR81]).

Prevention and Control {#Sec7}
======================

Vaccination and strict biosecurity measures are important for the prevention and control of IBV. Both live attenuated and killed vaccines are used to control IBV in commercial poultry farm. Since serotypes of IBV do not cross-protect each other, multivalent vaccine containing two or more antigenic types would be beneficial in providing broad protection (Cavanagh [@CR22]; Dhama et al. [@CR41]). In most countries, low virulent IBV vaccines are administered in day-old chicks with subsequent booster immunization with virulent vaccines in drinking water. Unlike highly virulent vaccine, low virulent IBV do not cause respiratory reaction. However, immunity produced by low virulent IBV is not always enough to protect the respiratory tract (Kataria et al. [@CR75]). Prior to immunization with oil-emulsion-inactivated vaccines, breeders and commercial egg layers are initially primed with live attenuated IBV vaccines in order to maintain a good level of local protection of the respiratory tract. Oil-emulsion-inactivated vaccines are given at 17 weeks of age (prior to egg laying of breeder or layer) and never during laying (Jackwood et al. [@CR62]; Liu et al. [@CR88]).

Embryonated chicken eggs are serially passaged with IBV strains to prepare live attenuated vaccines. Prolonged or lifelong immune response can be achieved through vaccination under optimal conditions (Cook et al. [@CR31]; Dhama et al. [@CR41]). Mass serotype, such as H120, is the most commonly used strain in live vaccines. Initially, birds are either vaccinated individually by eye drop instillation, intranasal and intratracheal routes, or mass vaccination by coarse spray or drinking water. Such mass vaccination procedures are cost-effective and induce both local and systemic immune responses. Ma5 is a single-component vaccine that can be included in first vaccination programs with IB 4/91 vaccines and inactivated vaccines. This type of vaccination program provides broad protection against different IBV serotypes. Selection of vaccine must be based on the prevalent strains in the local area. Administration of different vaccine strains together confers cross-protection against various field isolates in the SPF chicken (Li et al. [@CR84]; Marandino et al. [@CR95]). Combination of Mass and Conn or Mass and JMK provides higher degree of cross-protection to some heterologous strains. IB 4/91 serotype or IB 274 vaccine virus gives specific protection against IBV. These provide broad protection when combined with Ma5 and IB multi-vaccines (Ma et al. [@CR93]). Inactivated vaccines induce higher level of antibody response.

However, live vaccine plays a significant role in protecting commercial layers because of better induction of T cell response and local antibody (IgA) production. In North America, Mass, Conn, and Ark serotypes are included in both live attenuated and inactivated vaccines. California and Georgia 98 vaccine strains are being used in the United States. Holland variants such as D-274 and D-1466 along with the IB H120-based vaccines are used in most parts of Europe. Live, freeze-dried vaccine serotypes (Ma5 and 4/91) provide long-lasting protection. In Korea, newly evolving IBV recombinants can be controlled by K2 vaccine strain (Lim et al. [@CR86]). Mass vaccine strain is the only live attenuated vaccine approved in Brazil (Brandao [@CR14]). Vaccination program involves initial administration of Mass-type vaccine followed by a variant shown to be efficacious against Italy 02 and QX (Jones [@CR70]). The only vaccine strain used in India is Mass strain 41 (M41). DNA, subunit, and vectored vaccines using S1 glycoprotein gene and reverse genetics vaccines have been identified (Dhama et al. [@CR40]; Lin et al. [@CR87]). Protection against two or more serotypes can be achieved through introduction of antigen from two or more viruses in recombinant or vector-based vaccines. These new-generation vaccines can be administered safely in ovo, and efficacy is needed to be tested before introduction for commercial purposes (Matthijs et al. [@CR98]; Brandao [@CR14]; Ullah et al. [@CR122]). Recombinant IBV vaccine using fowl adenovirus vector backbone expressing the S1 glycoprotein gene provides different levels of protection against homologous challenge (Johnson et al. [@CR67]; Toro et al. [@CR121]).

The recent emergence demands the inclusion of QX-like IBV strains in the vaccination program against IB. Yan and coworkers attenuated the QX-like IBV strains by continuous passage in chicken embryos for 130 generations, and it was found to be safe and effective for inducing protection against QX-like IBV strains (Yan et al. [@CR130]). The accessory proteins 3a, 3b, 5a, and 5b contribute individually to the pathogenicity of IBV, and deleting any one of these genes results in attenuation of the virus and can be a potential vaccine candidate (Laconi et al. [@CR82]). Another research team also reported the deletion of accessory genes 3ab and/or 5ab in IBV resulting in attenuation with the ability to induce protection in chickens (van Beurden et al. [@CR123]). Recently, inactivated IBV vaccine encapsulated in chitosan nanoparticles induced an early and stronger IgA and IgG anti-IBV antibodies, when it was vaccinated alone or in association with a live attenuated vaccine (Lopes et al. [@CR90]).

Some of the alternative control measures have been tried and found to be partially successful for the control of IBV. The chicken TLR21 is a functional homologue of mammalian TLR9, recognizes CpG motif, and results in the induction of nuclear factor-kappa B (NF-κB) and its related cytokines (Brownlie et al. [@CR16]). Prophylactic administration of CpG to 18-day-old embryos decreased the viral load (Dar et al. [@CR33]). Astragalus polysaccharides isolated from a traditional Chinese medicinal herb, *Astragalus mongholicus*, inhibit IBV infection, in vitro, in a dose-dependent manner. The lower viral replication was associated with reduced mRNA levels of the proinflammatory cytokines IL-1β, IL-6, IL-8, and TNF-α (Zhang et al. [@CR135]).

Future Perspectives {#Sec8}
===================

Avian infectious bronchitis is one of the most difficult diseases to be controlled in the chicken. Continued emergence of different variants of IBV complicates the control program. Both live attenuated and killed vaccines are used in the field; however, IB outbreaks even in the vaccinated flocks are constantly reported from many parts of the world. Epidemiological surveillance and improved knowledge on the circulating field variants of IBV are necessary for implementing a better control program. Research works are still warranted for improving our understanding on immune response against IBV particularly cellular immunity and a strategic vaccine having capacity to control diverse variants of the virus.
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